A menudo se describe a Marte como un planeta con una corteza estancada: a diferencia de la Tierra, su superficie no se fragmenta por el movimiento de placas tectónicas. Dado que la tectónica de placas impulsa el vulcanismo, el reciclaje geológico y la formación de contine …
Grandes masas de magma en Marte pese a no tener tectónica de placas Read More »
Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.
With the latest round, Roche’s Genentech will have racked up nearly 450 layoffs in California over the last year amid ongoing restructuring. At the same time, the biotech is joining forces with Astex Pharmaceuticals in a deal that could surpass $490 million.
Genentech culls 103 jobs, inks $490M-plus biobucks deal with Astex Read More »
Hace unos diez mil millones de años, muchas galaxias dejaron de existir como estructuras individuales, al ser tragadas por otras galaxias mayores, o al colisionar y fusionarse con otras de masa similar. Nuestra galaxia consiguió sobrevivir como estructura mayormente individual …
La clave de cómo nuestra galaxia sobrevivió a la era más violenta del universo Read More »
Sumit Rana’s departure could be a significant leadership shakeup for Epic, as the president was viewed as a potential successor to the company’s 82 year-old CEO.
Los anficiónidos —coloquialmente conocidos como “perros-oso” (bear-dogs, en inglés)— fueron un grupo de carnívoros que prosperó en América del Norte y Eurasia durante buena parte del Cenozoico, desde el Eoceno hasta el Mioceno tardío. A …
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom Read More »
The rule, released Thursday, builds on Trump administration’s priorities, including cutting Medicare reimbursement for drugs in the controversial 340B program and equalizing payment between sites of care.
The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations of existing therapies.
Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree Read More »
Scribe Therapeutics’ pipeline is immature, with its lead program recently greenlit for first-in-human testing. The biotech is working on CRISPR-based therapies for cardiometabolic diseases.
Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios Read More »
